14 Ovarian Cancer Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Ovarian Cancer Studies in Birmingham

NCT04251052Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 muta...

Birmingham, ALNA1,956 participantsNRG Oncology

View Study Details

NCT07213804Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube canc...

Birmingham, ALPHASE31,630 participantsEli Lilly and Company

View Study Details

NCT07218809Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ova...

Birmingham, ALPHASE31,100 participantsAstraZeneca

View Study Details

NCT07318558Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemot...

Birmingham, ALPHASE3900 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03564340Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of...

Birmingham, ALPHASE1890 participantsRegeneron Pharmaceuticals

View Study Details

NCT06580314Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III o...

Birmingham, ALPHASE3880 participantsNRG Oncology

View Study Details

NCT06824467Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevaciz...

Birmingham, ALPHASE3770 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06787612Recruiting

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see h...

Birmingham, ALPHASE2297 participantsRegeneron Pharmaceuticals

View Study Details

NCT06906341Recruiting

Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cance...

Birmingham, ALPHASE2270 participantsCorcept Therapeutics

View Study Details

NCT06303505Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in ...

Birmingham, ALPHASE1250 participantsTubulis GmbH

View Study Details

NCT06890338Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuxim...

Birmingham, ALPHASE2140 participantsAbbVie

View Study Details

NCT07690189Recruiting

Study of NTB-928 in R/R OC

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how N...

Birmingham, ALPHASE190 participantsTeneoSeven, Inc.

View Study Details

NCT04606914Recruiting

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed,...

Birmingham, ALPHASE270 participantsUniversity of Alabama at Birmingham

View Study Details

NCT05952453Recruiting

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there w...

Birmingham, ALPHASE220 participantsUniversity of Alabama at Birmingham

View Study Details

About Ovarian Cancer Clinical Trials in Birmingham

Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.

There are currently 14 ovarian cancer clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 9,263 participants. Research is being sponsored by NRG Oncology, Eli Lilly and Company, AstraZeneca and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ovarian Cancer Clinical Trials in Birmingham — FAQ

Are there ovarian cancer clinical trials in Birmingham?

Yes, there are 14 ovarian cancer clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What ovarian cancer treatments are being tested?

The 14 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.

Data updated September 1, 2026 from ClinicalTrials.gov